These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 2495641

  • 1. OKT3 delays rejection crises after heart transplantation.
    Weimar W, Essed CE, Balk AH, Simoons ML, Hendriks GF, Wenting GJ, Mochtar B, Bos E.
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2497-8. PubMed ID: 2495641
    [No Abstract] [Full Text] [Related]

  • 2. Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation.
    Macris MP, Frazier OH, Lammermeier D, Radovancevic B, Duncan JM.
    J Heart Transplant; 1989 Feb; 8(4):281-7. PubMed ID: 2504894
    [Abstract] [Full Text] [Related]

  • 3. OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation.
    Hegewald MG, O'Connell JB, Renlund DG, Lee HR, Burton NA, Karwande SV, Jones KW, Lassetter JE, Bristow MR.
    J Heart Transplant; 1989 Feb; 8(4):303-9; discussion 309-10. PubMed ID: 2504897
    [Abstract] [Full Text] [Related]

  • 4. Nursing implications of immunosuppression in transplantation.
    Shaefer M, Williams L.
    Nurs Clin North Am; 1991 Jun; 26(2):291-314. PubMed ID: 1904575
    [Abstract] [Full Text] [Related]

  • 5. Prophylactic use of OKT3 in cardiac transplantation.
    Konertz W, Weyand M, Friedl A.
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2494-6. PubMed ID: 2495640
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Selective use of OKT3 in heart transplantation with the use of risk factor analysis.
    Macris MP, Van Buren CT, Sweeney MS, Frazier OH, Duncan JM.
    J Heart Transplant; 1989 Feb; 8(4):296-302. PubMed ID: 2504896
    [Abstract] [Full Text] [Related]

  • 8. Treating cardiac allograft rejection: present approach--analysis of 100 consecutive patients.
    Radovancevic B, Birovljev S, Frazier OH.
    J Heart Transplant; 1990 Feb; 9(3 Pt 2):288-91. PubMed ID: 2113091
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The prophylactic use of Orthoclone OKT3 in kidney and heart transplantation.
    Weimar W, Baumgartner D, Hendriks GF, Hesse CJ, Balk AH, Simoons ML, Bos E.
    Transplant Proc; 1988 Oct; 20(5 Suppl 6):96-100. PubMed ID: 3140455
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Orthoclone OKT3 and cardiac transplantation: an overview.
    Mahon PM.
    Crit Care Nurse; 1991 Sep; 11(8):42-7, 50. PubMed ID: 1909947
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Fibrinoid necrosis of a temporal artery complicating the treatment of refractory cardiac allograft rejection with murine monoclonal CD3 antibody (OKT3).
    Hammond EH, Watson FS, Bristow MR, O'Connell JB, Gilbert EM, Doty DB, Renlund DG.
    J Heart Transplant; 1990 Sep; 9(3 Pt 1):236-8. PubMed ID: 2113090
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.